Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.07, read 2026-10-28
Ethical does not pass the values gate
Price11.52 USD
Fair value9.99
Ethical score70.0/100
Our investment reviews on this name
2026-10-26Read Accumulation10.13+13.7% to today ✓Markup gives way to Accumulation
2026-08-21Read Markup9.70+18.8% to today ✓Distribution gives way to Markup after a 35% rise in 7 weeks
2026-07-02Read Distribution7.17+60.7% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Arhaus, Inc. holds its Accumulation at $11.52. The statistical read favours the buyers, held for 8 days.
As held on the ledger · 2026-10-28
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 8 days
Price at the screen
$11.52
Valuation
17.46 trailing · 15.36 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.32
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
41.63%
Below 33%
Interest-bearing debt is 41.6% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
18.21%
Below 49%
Money owed to the company is 18.2% of assets, under the 49% limit.
Pass
Revenue purity
0.22%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Arhaus,'s business is in a permissible area, but its interest-bearing debt is about 42% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ARHS's ethical verdict changes
Today ARHS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. The price runs 13.3% above the base estimate.
Third-party analyst targets: 13 covering, consensus None. The average target sits −13% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Home Furnishings Chain Sits at Modest Valuation
Imagine kitting out a living room with premium sofas and dining tables. Arhaus sells exactly that across the United States, yet revenue growth has slowed to a bare 1 percent. The stock trades at 13.9 times forward earnings with a 26 percent margin of safety to our fair value, but we see no opportunity here because the business lacks the momentum that would turn a reasonable multiple into an attractive one.
A consumer cyclical name with 5 percent profit margins and 18 percent ROE can look tempting when earnings sit near recent peaks. Low single-digit growth however turns that low multiple into a warning rather than a bargain, and the unknown moat leaves the firm exposed to bigger rivals and shifting tastes in specialty retail.
Consumer spending swings remain the obvious risk in any housing slowdown, while the analyst median target of 8 dollars sits only modestly above the current price. The ethical screen raises no concerns. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ARHS trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Accumulation$11.52+13.7%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 13.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 35% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (13 analysts) rates it none, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 35% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (13 analysts) rates it none, with a mean price target of $9.
2026-10-19Markup$10.13+4.5%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (13 analysts) rates it none, with a mean price target of $9.
2026-10-12Markup$9.69+11.0%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (13 analysts) rates it none, with a mean price target of $9.
2026-10-02Markup$8.73+0.0%Entry 8
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (13 analysts) rates it none, with a mean price target of $9.
2026-09-24Markup$8.73-10.0%Entry 7
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 10.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (13 analysts) rates it none, with a mean price target of $9. Since the last review it its composite score rose; its composite score eased.
2026-08-21Markup · changed$9.70+26.1%Entry 6
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 26.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (13 analysts) rates it none, with a mean price target of $9.
2026-07-21Distribution$7.69+7.3%Entry 5
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 7.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (13 analysts) rates it none, with a mean price target of $9.
2026-07-18Distribution$7.17+0.0%Entry 4
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (13 analysts) rates it none, with a mean price target of $9.
2026-07-17Distribution$7.17+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (13 analysts) rates it none, with a mean price target of $9.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
